VistaGen Therapeutics (NASDAQ:VTGN) appointed Dr. Mark Wallace to its clinical advisory board to advanced the company’s non-opioid neuropathic pain treatment.
As quoted in the press release:
“We are fortunate to have attracted renowned CNS clinical and regulatory experts to support our development plans and regulatory strategies for AV-101, experts such as Drs. Carlos Zarate Jr., Maurizio Fava, Gerard Sanacora, Sanjay Mathew, Thomas Laughren, and now, Dr. Mark Wallace,” stated Shawn Singh, Chief Executive Officer of VistaGen. “While the primary clinical development focus of our lead oral CNS product candidate, AV-101, remains on major depressive disorder, we are confident of AV-101’s potential to impact additional CNS indications with unmet need, where modulation of NMDA receptors, activation and involvement of AMPA pathways and/or key active metabolites of AV-101 may achieve therapeutic benefit, including neuropathic pain. Dr. Wallace brings extensive experience to our clinical advisory team. His knowledge and input will be among the key drivers in VistaGen’s success.”
Dr. Mark Wallace commented, “I am delighted to join VistaGen’s Clinical Advisory Board at this critical inflection point for the Company. I am intrigued by AV-101’s mechanism of action and Phase 1 study data demonstrating AV-101’s potential to reduce pain safely and effectively, without causing negative side effects like many other neuropathic pain treatments, including gabapentin. I look forward to applying the insights I have acquired through many years of practical experience researching and treating neuropathic pain to support VistaGen’s clinical development objectives.”